US judge denies initial attempt by Novartis to block generic Entresto launch
Novartis’s bid to block the launch of a biosimilar for its best-selling drug Entresto (sacubitril/valsartan) got off to a faltering…
Cardiovascular
-
-
Bayer set to expand Kerendia’s label in cardiology with Phase III win
Bayer is looking to expand the use of Kerendia (finerenone) beyond type 2 diabetes (T2D), as the therapy showed efficacy…
-
MHRA approves Novo Nordisk’s semaglutide to cut cardiovascular risk
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication of Novo Nordisk’s semaglutide, marketed as…
-
Cardurion closes $260m in Series B to develop cardiovascular pipeline
US-based cardiology biotech Cardurion Pharmaceuticals has raised $260m in Series B financing to advance its drug pipeline. The proceeds will…
-
Novo Nordisk’s ocedurenone Phase III flop costs company $816m
Novo Nordisk has said it will take a DKr5.7bn ($816m) hit after its acquired drug ocedurenone flopped in the Phase…
-
Tectonic bets on GPCR heart failure drug following reverse merger with Avrobio
Tectonic Therapeutic has completed a reverse merger with Avrobio and will begin trading on the Nasdaq global market as Tectonic…
-
Marea launches with $190m to develop cardiometabolic therapies
Clinical-stage biotechnology company Marea Therapeutics has launched with funding of $190m secured through combined Series A and B rounds to…
-
AstraZeneca champions early kidney disease diagnosis with modelling data
AstraZeneca has highlighted both the economic and environmental benefits of implementing early, targeted screening for chronic kidney disease (CKD). CKD…
-
EC grants orphan medicinal product status to Rocket’s RP-A601
The European Commission (EC) has granted orphan medicinal product designation for Rocket Pharmaceuticals’ RP-A601 gene therapy candidate to treat plakophilin-2…
-
AstraZeneca selects new heart failure target with BenevolentAI
AstraZeneca has incorporated a new target for heart failure treatment into its discovery portfolio through its ongoing collaboration with BenevolentAI.…
